|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahmad A and Gadgeel SM: Lung cancer and
personalized medicine: Novel therapies and clinical management. Adv
Exp Med Biol. 890:v–vi. 2016.PubMed/NCBI
|
|
4
|
NSCLC Meta-analysis Collaborative Group, .
Preoperative chemotherapy for non-small-cell lung cancer: A
systematic review and meta-analysis of individual participant data.
Lancet. 383:1561–1571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spicer J, Wang C, Tanaka F, Saylors GB,
Chen KN, Liberman M, Vokes E, Girard N, Lu S, Provencio M, et al:
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab
(NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as
neoadjuvant treatment for patients with resectable non-small cell
lung cancer (NSCLC). J Clin Oncol. 39 (Suppl 15):S85032021.
View Article : Google Scholar
|
|
6
|
Wakelee HA, Altorki NK, Zhou C, Csőszi T,
Vynnychenko IO, Goloborodko O, Goloborodko O, Luft A, Akopov A,
Martinez-Marti A, Kenmotsu H, et al: IMpower010: Primary results of
a phase III global study of atezolizumab versus best supportive
care after adjuvant chemotherapy in resected stage IB-IIIA
non-small cell lung cancer (NSCLC). J Clin Oncol. 39 (Suppl
15):S85002021. View Article : Google Scholar
|
|
7
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Relli V, Trerotola M, Guerra E and Alberti
S: Abandoning the notion of non-small cell lung cancer. Trends Mol
Med. 25:585–594. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawase A, Yoshida J, Ishii G, Nakao M,
Aokage K, Hishida T, Nishimura M and Nagai K: Differences between
squamous cell carcinoma and adenocarcinoma of the lung: are
adenocarcinoma and squamous cell carcinoma prognostically equal?
Jpn J Clin Oncol. 42:189–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Detterbeck FC, Socinski MA, Gralla RJ,
Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman
MB, Ye Z, et al: Neoadjuvant chemotherapy with
gemcitabine-containing regimens in patients with early-stage
non-small cell lung cancer. J Thorac Oncol. 3:37–45. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pataer A, Weissferdt A, Vaporciyan AA,
Correa AM, Sepesi B, Wistuba II, Heymach JV, Cascone T and Swisher
SG: Evaluation of pathologic response in lymph nodes of patients
with lung cancer receiving neoadjuvant chemotherapy. J Thorac
Oncol. 16:1289–1297. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Azam F, Latif MF, Farooq A, Tirmazy SH,
AlShahrani S, Bashir S and Bukhari N: Performance status assessment
by using ECOG (eastern cooperative oncology group) score for cancer
patients by oncology healthcare professionals. Case Rep Oncol.
12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pataer A, Kalhor N, Correa AM, Raso MG,
Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, et al:
Histopathologic response criteria predict survival of patients with
resected lung cancer after neoadjuvant chemotherapy. J Thorac
Oncol. 7:825–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emens LA and Middleton G: The interplay of
immunotherapy and chemotherapy: Harnessing potential synergies.
Cancer Immunol Res. 3:436–443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang BY, Huang JY, Chen HC, Lin CH, Lin
SH, Hung WH and Cheng YF: The comparison between adenocarcinoma and
squamous cell carcinoma in lung cancer patients. J Cancer Res Clin
Oncol. 146:43–52. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Junker K, Thomas M, Schulmann K, Klinke F,
Bosse U and Müller KM: Tumour regression in non-small-cell lung
cancer following neoadjuvant therapy. Histological assessment. J
Cancer Res Clin Oncol. 123:469–477. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waser N, Adam A, Schweikert B, Vo L,
McKenna M, Breckenridge M, Penrod JR and Goring S: 1243P Pathologic
response as early endpoint for survival following neoadjuvant
therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC):
Systematic literature review and meta-analysis. Ann Oncol. 31
(Suppl 4):S8062020. View Article : Google Scholar
|
|
23
|
Rosner S, Liu C, Forde PM and Hu C:
Association of pathologic complete response and long-term survival
outcomes among patients treated with neoadjuvant chemotherapy or
chemoradiotherapy for NSCLC: A meta-analysis. JTO Clin Res Rep.
3:1003842022.PubMed/NCBI
|
|
24
|
Forde PM, Chaft JE and Pardoll DM:
Neoadjuvant PD-1 blockade in resectable lung cancer. N Eng J Med.
379:e142018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Eng J Med. 378:2078–2092. 2018.
View Article : Google Scholar
|
|
26
|
Reck M, Shankar G, Lee A, Coleman S,
McCleland M, Papadimitrakopoulou VA, Socinski MA and Sandler A:
Atezolizumab in combination with bevacizumab, paclitaxel and
carboplatin for the first-line treatment of patients with
metastatic non-squamous non-small cell lung cancer, including
patients with EGFR mutations. Exp Rev Respir Med. 14:125–136. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H,
Chaft JE, Tan KS, Jones DR, Kris MG, Adusumilli PS and Travis WD:
Pathologic assessment after neoadjuvant chemotherapy for NSCLC:
Importance and implications of distinguishing adenocarcinoma from
squamous cell carcinoma. J Thorac Oncol. 14:482–493. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Q, Fu YY, Yue QN, Wu Q, Tang Y, Wang
WY, Wang YS and Jiang LL: Distribution of PD-L1 expression and its
relationship with clinicopathological variables: an audit from 1071
cases of surgically resected non-small cell lung cancer. Int J Clin
Exp Pathol. 12:774–786. 2019.PubMed/NCBI
|
|
29
|
Choi NC, Carey RW, Daly W, Mathisen D,
Wain J, Wright C, Lynch T, Grossbard M and Grillo H: Potential
impact on survival of improved tumor downstaging and resection rate
by preoperative twice-daily radiation and concurrent chemotherapy
in stage IIIA non-small-cell lung cancer. J Clin Oncol. 15:712–722.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Travis WD, Dacic S, Wistuba I, Sholl L,
Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et
al: IASLC multidisciplinary recommendations for pathologic
assessment of lung cancer resection specimens after neoadjuvant
therapy. J Thorac Oncol. 15:709–740. 2020. View Article : Google Scholar : PubMed/NCBI
|
